Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FATE-NK100 · 1 trial · 11 indications
The incidence of dose-limiting toxicity (DLT) within each dose cohort within the first 28 days after FATE-NK100 administration (ie, Day 1 through Day 29).
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. |
| Regimen B | EXPERIMENTAL | FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors. |
| Regimen C | EXPERIMENTAL | Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors. |
| Name | Type | Description |
|---|---|---|
| FATE-NK100 | DRUG | FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity |
| Cetuximab | DRUG | Epidermal growth factor receptor inhibitor antineoplastic agent |
| Trastuzumab | DRUG | HER2/neu receptor inhibitor |
Inclusion Criteria: 1. Regimen A only (monotherapy): Subjects with advanced metastatic solid tumors 2. Regimen B only (combination with trastuzumab): Subjects with advanced metastatic HER2+ solid tumors 3. Regimen C only (combination with cetuximab): Subjects with advanced metastatic EGFR+ solid tu...
FATE-NK100 is an investigational cell therapy being studied for the treatment of HER2 positive gastric cancer, along with other advanced solid tumors including colorectal cancer, head and neck squamous cell carcinoma, EGFR positive solid tumors, HER2-positive breast cancer, hepatocellular carcinoma, non small cell lung cancer, renal cell carcinoma, pancreatic cancer, and melanoma.
FATE-NK100 is being developed by Fate Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol FATE.
FATE-NK100 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 trial of FATE-NK100 has been completed.
FATE-NK100 has been studied in a completed Phase 1 clinical trial with the identifier NCT03319459. The trial evaluated FATE-NK100 as a monotherapy and in combination with a monoclonal antibody in subjects with advanced solid tumors, including HER2 positive gastric cancer.
Yes, FATE-NK100 is classified as a small molecule modality in the oncology therapeutic area. It is being investigated for the treatment of HER2 positive gastric cancer and other advanced solid tumors.